Nothing Special   »   [go: up one dir, main page]

BR0207307A - Inibidores de glyt-1 - Google Patents

Inibidores de glyt-1

Info

Publication number
BR0207307A
BR0207307A BR0207307-2A BR0207307A BR0207307A BR 0207307 A BR0207307 A BR 0207307A BR 0207307 A BR0207307 A BR 0207307A BR 0207307 A BR0207307 A BR 0207307A
Authority
BR
Brazil
Prior art keywords
glyt
inhibitors
neurological
pharmaceutical
compound
Prior art date
Application number
BR0207307-2A
Other languages
English (en)
Inventor
Ian Egle
William Delaney
Zhaoqing Wang
Richard Shumacher
Allen T Hopper
Ashok Tehim
Shawn Maddaford
Original Assignee
Allelix Neuroscience Inc
Nps Allelix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23026417&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0207307(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allelix Neuroscience Inc, Nps Allelix Corp filed Critical Allelix Neuroscience Inc
Publication of BR0207307A publication Critical patent/BR0207307A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

INIBIDORES DE GlyT-1". A presente invenção proporciona um produto farmacêutico para o tratamento de distúrbios neurológicos e psiquiátricos, compreendendo um composto de fórmula (I) ou um sal farmaceuticamente aceitável do mesmo.
BR0207307-2A 2001-02-16 2002-02-15 Inibidores de glyt-1 BR0207307A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26924101P 2001-02-16 2001-02-16
PCT/CA2002/000176 WO2002066456A2 (en) 2001-02-16 2002-02-15 Thiophene substituted amine derivatives as glyt-1 inhibitors

Publications (1)

Publication Number Publication Date
BR0207307A true BR0207307A (pt) 2004-08-17

Family

ID=23026417

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207307-2A BR0207307A (pt) 2001-02-16 2002-02-15 Inibidores de glyt-1

Country Status (31)

Country Link
US (1) US6667336B2 (pt)
EP (1) EP1368336B9 (pt)
JP (2) JP2004523548A (pt)
KR (1) KR100900020B1 (pt)
CN (1) CN1219776C (pt)
AT (1) ATE327986T1 (pt)
AU (1) AU2002235682C1 (pt)
BG (1) BG108164A (pt)
BR (1) BR0207307A (pt)
CA (1) CA2438367A1 (pt)
CY (1) CY1105529T1 (pt)
CZ (1) CZ20032503A3 (pt)
DE (1) DE60211866T2 (pt)
DK (1) DK1368336T3 (pt)
EA (1) EA006636B1 (pt)
EE (1) EE05329B1 (pt)
ES (1) ES2266446T3 (pt)
HK (1) HK1061025A1 (pt)
HR (1) HRP20030696A2 (pt)
HU (1) HUP0303185A3 (pt)
IL (1) IL157194A (pt)
MX (1) MXPA03007309A (pt)
NO (1) NO329038B1 (pt)
NZ (1) NZ527695A (pt)
PL (1) PL365024A1 (pt)
PT (1) PT1368336E (pt)
SI (1) SI1368336T1 (pt)
SK (1) SK287304B6 (pt)
UA (1) UA75114C2 (pt)
WO (1) WO2002066456A2 (pt)
ZA (1) ZA200307201B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191165B1 (en) * 1996-05-31 2001-02-20 Allelix Neuroscience Inc. Pharmaceutical for treatment of neurological and neuropsychiatric disorders
ATE456366T1 (de) * 2004-12-16 2010-02-15 Janssen Pharmaceutica Nv Kombination aus einem glycin-transporter (glyt1) hemmer und einem antipsychotikum zur behandlung von symptomen von schizophrenie und ihre herstellung und verwendung
US20090253918A1 (en) * 2006-10-02 2009-10-08 Janssen Pharmaceuticals, N.V. Novel intermediate for glyt1 inhibitor
WO2008065500A2 (en) * 2006-11-30 2008-06-05 Pfizer Products Inc. Heteroaryl amides as type i glycine transport inhibitors
CN103374057B (zh) * 2012-04-16 2015-08-19 中国医药集团总公司四川抗菌素工业研究所 一种对甘氨酸转运子具有抑制活性的化合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3050800C2 (pt) 1979-03-22 1989-06-22 Continental Pharma Inc., Bruessel/Bruxelles, Be
BE885303A (fr) 1980-09-19 1981-03-19 Continental Pharma Glycinamides
US4383999A (en) 1981-05-26 1983-05-17 Smithkline Beckman Corporation Inhibition of GABA uptake by N-substituted azaheterocyclic carboxylic acids and their esters
AU552050B2 (en) 1981-05-26 1986-05-22 Smithkline Beckman Corporation N-substituted azeheterocyclic carboxylic acids and their esters
US4514414A (en) 1982-10-25 1985-04-30 Smithkline Beckman Corporation N-Substituted pyrrolidineacetic acids and their esters
DK288385D0 (da) 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
US4772615A (en) 1985-11-08 1988-09-20 Warner-Lambert Company Various N-substituted 3-piperidine carboxylic acids or N-substituted 3-pyridinecarboxylic acids and derivatives thereof
FI864246A (fi) 1985-11-08 1987-05-09 Warner Lambert Co N-substituerade 3-piperidin- eller 3-pyridinkarboxylsyror samt deras derivat.
DK165692C (da) 1986-01-07 1993-11-08 Novo Nordisk As Phenylbutenderivater, fremgangsmaade til fremstilling heraf, farmaceutisk praeparat indeholdende disse, samt anvendelse af disse til fremstilling af et medikament nyttigt til inhibering af gaba-optagelse i mennesker
JPH02129158A (ja) 1988-11-07 1990-05-17 Nippon Steel Corp 光学活性なグリシン誘導体及びその製造方法
IE913279A1 (en) * 1990-09-26 1992-04-08 Astra Ab (2-Thienyl)alkylamine Derivatives Having Neuroprotective¹Properties
ES2036926B1 (es) 1991-08-08 1994-01-16 Uriach & Cia Sa J "procedimiento para la obtencion de derivados de la (2-alquil-3-piridil)metilpiperazina".
IL124536A (en) 1995-12-07 2001-03-19 Daniel C Javitt Pharmaceutical compositions containing a glycine uptake antagonist
EP1014966B1 (en) * 1996-05-31 2006-08-02 Allelix Neuroscience Inc. Pharmaceutical for treatment of neurological and neuropsychiatric disorders
US6191165B1 (en) 1996-05-31 2001-02-20 Allelix Neuroscience Inc. Pharmaceutical for treatment of neurological and neuropsychiatric disorders
ATE218537T1 (de) * 1996-07-22 2002-06-15 Novo Nordisk As Verbindungen mit wachstumshormon freisetzenden eigenschaften
HUP0101300A3 (en) * 1998-01-09 2002-11-28 Pfizer Matrix metalloprotease inhibitors
US6103743A (en) * 1999-08-06 2000-08-15 Allelix Neuroscience, Inc. Unsaturated amino acid derivatives

Also Published As

Publication number Publication date
US20030176489A1 (en) 2003-09-18
CY1105529T1 (el) 2010-07-28
KR20040028719A (ko) 2004-04-03
EE200300394A (et) 2003-12-15
NZ527695A (en) 2005-05-27
CA2438367A1 (en) 2002-08-29
DE60211866T2 (de) 2007-06-14
JP2004523548A (ja) 2004-08-05
CZ20032503A3 (cs) 2004-02-18
BG108164A (en) 2004-07-30
UA75114C2 (en) 2006-03-15
ATE327986T1 (de) 2006-06-15
JP2010059182A (ja) 2010-03-18
WO2002066456A2 (en) 2002-08-29
DK1368336T3 (da) 2006-10-02
CN1491221A (zh) 2004-04-21
HUP0303185A2 (hu) 2003-12-29
NO329038B1 (no) 2010-08-02
IL157194A (en) 2006-12-31
AU2002235682C1 (en) 2008-12-11
HUP0303185A3 (en) 2008-12-29
SI1368336T1 (sl) 2006-10-31
EA200300900A1 (ru) 2004-02-26
NO20033634L (no) 2003-10-08
PL365024A1 (en) 2004-12-27
AU2002235682B2 (en) 2007-04-26
HRP20030696A2 (en) 2005-04-30
CN1219776C (zh) 2005-09-21
EE05329B1 (et) 2010-08-16
ZA200307201B (en) 2004-07-28
US6667336B2 (en) 2003-12-23
MXPA03007309A (es) 2004-06-30
HK1061025A1 (en) 2004-09-03
EA006636B1 (ru) 2006-02-24
ES2266446T3 (es) 2007-03-01
SK287304B6 (sk) 2010-06-07
KR100900020B1 (ko) 2009-06-01
SK11442003A3 (sk) 2004-03-02
EP1368336A2 (en) 2003-12-10
WO2002066456A3 (en) 2002-10-17
PT1368336E (pt) 2006-10-31
EP1368336B9 (en) 2007-02-14
EP1368336B1 (en) 2006-05-31
NO20033634D0 (no) 2003-08-15
DE60211866D1 (de) 2006-07-06

Similar Documents

Publication Publication Date Title
IL127244A0 (en) Pharmaceutical for treatment of neurological and neuropsychiatric disorders
BR0109703A (pt) Derivados de piperazina
ATE440603T1 (de) 8-hydroxychinolinderivate
BR0111892A (pt) Bis-arilsulfonas
BR0209812A (pt) Uso de osteopontina para o tratamento e/ou a prevenção de doenças neurológicas
BR0113590A (pt) 7-oxo-piridopirimidinas
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
SE0101082D0 (sv) Novel use
BR0207307A (pt) Inibidores de glyt-1
BR0110871A (pt) Derivados de sulfonamida
BR0211223A (pt) Derivados de 4-aminociclohexanol substituìdos
BR0110874A (pt) Derivados de sulfonamida
DE60204882D1 (de) Zykloalkenylsulfonamidderivate
BR0316751A (pt) Análogos de gabapentina para fibromialgia e outros distúrbios relacionados
BR0308911A (pt) Composto, composição farmacêutica, métodos de tratamento de dor e de enxaqueca, e, uso de um composto
TNSN99158A1 (ar) طريقة لمنع الاصابة بالربو
BR0116724A (pt) Composto, método de tratamento de um distúrbio neurológico ou de uma doença neurodegenerativa, método de tratamento de dor, composição farmacêutica, uso de um composto, e, processos para a preparação e para a sìntese de um composto
WO2002053555A3 (en) Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
WO2002053556A3 (en) Pyrrolidinylmethyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
BR0116672A (pt) Sal farmaceuticamente aceitável de um composto, composto, composição farmacêutica, uso de um sal farmaceuticamente aceitável, e, processo para preparar um composto
AU6876200A (en) Remedies for nervous diseases

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: NPS PHARMACEUTICALS, INC. (US)

Free format text: TRANSFERIDO DE: ALLELIX NEUROSCIENCE, INC. E NPS ALLELIX CORP.

B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 10A, 11A E 12A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 10A, 11A, 12A, 13A, 14A, 15A, 16A, 17A E 18A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.